The US is expressing concerns over EU pharmaceutical rules, potentially impacting the industry. There are reports that the EU may adjust its foreign subsidy rules to focus on larger deals due to concerns over red tape. The situation appears to be part of a broader trade tension, with the US also applying pressure on other fronts, although the specifics and potential outcomes are unclear.